WHO ICTRP trial
A Phase 3, Clinical Pharmacology Study of TAK-438 (20 mg, 40 mg) in Patients…
JPRN-jRCT2080221838 · Japan Primary Registries Network (JPRN)
Key facts
| Trial ID | JPRN-jRCT2080221838 |
|---|---|
| Public title | A Phase 3, Clinical Pharmacology Study of TAK-438 (20 mg, 40 mg) in Patients with PPI-Resistant Erosive Esophagitis |
| Scientific title | A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Dose-Response Relationships of Acid-Inhibitory Effect and Efficacy of TAK-438 (20 mg, 40 mg) in Patients with PPI-Resistant Erosive Esophagitis. |
| Primary sponsor | TAKEDA PHARMACEUTICAL COMPANY LTD. |
| Registry | Japan Primary Registries Network (JPRN) |
| Study type | Interventional |
| Phase | 3 |
| Conditions | Erosive esophagitis |
| Interventions | investigational material(s) Generic name etc : TAK-438 INN of investigational material : Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investigational material : 20 mg/day , 40 mg/day |
| Registration date | Jun 25, 2012 |
| Target size | 19 |
| Secondary IDs | JapicCTI-121882 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: